Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer

• Main Authors: Helen Creedon (Author), Lucy A. Balderstone (Author), Morwenna Muir (Author), Jozef Balla (Author), Laura Gomez-Cuadrado (Author), Natasha Tracey (Author), Joseph Loane (Author), Teresa Klinowska (Author), William J. Muller (Author), Valerie G. Brunton (Author)
• Format: Book
• Published: The Company of Biologists, 2016-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Resistance to human epidermal growth factor receptor 2 (HER2)-targeted therapies presents a major clinical problem. Although preclinical studies have identified a number of possible mechanisms, clinical validation has been difficult. This is most likely to reflect the reliance on cell-line models th...